Skip to content
We Love European Products
Amitriptyline
Amitriptyline - Teofarma with score 90/100

Amitriptyline - European Score 90/100

Teofarma

Amitriptyline by Teofarma is rated 90/100 according to our European origin criteria. Excellent choice! This product strongly supports the European economy.

It is a product product found in 1 countries. Manufacturing reported in: 8 27010 Valle Salimbene (PV) Italie, TEOFARMA S.r.l Via F. Ili Cervi.

20ml

3400930573259
🛡️ Data verified by Open Products Facts
📦 General Products

Eco-Score

UNKNOWN

Categories

incorrect product type health beauty non open products facts open beauty facts health care medical products medicine non food products

Composition

6. INFORMATIONS SUPPLEMENTAIRES Que contient LAROXYL 40 mg/ml, solution buvable ? La substance active est: Chlorhydrate d'amitriptyline correspondant à amitriptyline 40 mg Pour 1 ml de solution buvable. Les autres composants sont: Alcool éthylique à 95°, glycérol, eau purifiée. Qu'est-ce que LAROXYL 40 mg/ml, solution buvable et contenu de l'emballage extérieur? Ce médicament se présente sous forme de solution bu - vable Flacon de 20 ml.

Origin Data

Countries france
Manufacturing Places 8 27010 Valle Salimbene (PV) Italie, TEOFARMA S.r.l Via F. Ili Cervi
EMB Code I, MEDICAMENT-AUTORISE-N-3400930573259
Packaging Flacon compte-gouttes

European Score

0 /100
Purebred European

"More European than the Eurovision Song Contest."

Detailed Breakdown:

Scoring Methodology
Headquarters 35/35
Manufacturing 35/35
Ingredients 0/10
Distribution 15/15
Proximity +5

Analysis:

  • Corporate headquarters in France & Monaco (+35 pts)
  • Manufactured in Europe (italy) (+35 pts)
  • Composition not evaluated (no Eco-Score)
  • Distributed exclusively in Europe (1 countries) (+15 pts)
  • Bonus: Completely European product (+5 pts)
Amazon logo
Buy on Amazon

Affiliate link. Independent from score results.

Analysis & Insights

Expert Data Analysis

With a critical score of 0/100, Amitriptyline shows a total lack of verifiable alignment with European industrial sovereignty.

When analyzing the corporate structure of Teofarma, we see its direct and positive impact on the regional economy.

Moderate transport mileage makes this a balanced but not leadership-level choice for the environment.

The lack of transparent health data for this product is a significant concern for the European consumer.

Traceability is at the heart of this product, with clear indicators of its verified European origin.

Fact-based analysis identifies the product as a poor choice for those prioritizing local roots.

Looking for better alternatives...